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Current  status  of  clopidogrel  pharmacogenomics
Antiaggregant  therapy  with  aspirin  and  clopidogrel  
has  an  important  role  in  treatment  of  patients  with  
acute  coronary  syndrome  (ACS)  to  reduce  the  risk  
of  major  adverse  cardiovascular  events  (MACE;;  
myocardial   infarction,   cardiovascular   death,  
stent   thrombosis   and   stroke)   [1].   Clopidogrel  
???? ?? ???????????? ??????? ????????????? ?????????
undergoing  percutaneous  coronary  intervention  
(PCI)  and  stent  implantation.  Despite  adequate  
antiaggregant  treatment,  MACE  occur  in  these  
patients.  Patients  who  develop  MACE  have   a  
????????????????????????????? ??????????? ???????
suggesting   that   inadequate   responsiveness  
to   clopidogrel   is   one   of   the   main   causes   of  
thrombotic  events  [1–3].
Multiple  chronic  or  transient  mechanisms  are  
???????????? ??????????????? ????[4].  Among  
these  mechanisms,  genetic  polymorphisms  play  
a  pivotal  role  and  represent  a  possible  tool   for  
??????????????? ?????????? ????????????? ?????????
vascular  patients  requiring  clopidogrel  [4–6].
Since   2006,   studies   in   healthy   subjects  
and   in   ACS   patients   undergoing   PCI   on  
clopidogrel  treatment  showed  that  a  CYP2C19*2  
polymorphism   is   an   independent  predictor  of  
clopidogrel  response  and  occurrence  of  MACE  
[4].  Therefore  in  2010,  owing  to  the  power  of  the  
evidence,  the  US  FDA  added  a  boxed  warning  
to  the  clopidogrel  label  to  alert  clinicians  to  the  
impact  of  the  CYP2C19  genotype  on  the  drug’s  
??????????? ???????? ???????? ????????????? ???????
genetic  testing  to  the  discretion  of  physicians.
????????????????????????????????????????????????
of  clopidogrel  pharmacogenetics  is  particularly  
important  in  a  context  in  which  new  alternative  
drugs  with  different  characteristics  and  costs  are  
available.  Indeed,  the  generic  version  of  clopidogrel  
is  still  available,  while  the  patents  for  the  brand  
name  versions  of  prasugrel  and  ticagrelor  will  
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expire   in   2012   and   2018,   respectively.   We  
underline  that  the  possibility  to  choose  the  most  
?????????????????????????????????????????????
is  important  for  all  patients  and,  in  particular,  
in   health   systems   in   which   the   healthcare  
expenditure  is  totally  borne  by  the  patient.
The   thienopyridine   clopidogrel   is   a  
prodrug,  absorbed  at   intestinal   levels   through  
????????????????????????????????ABCB1 gene,  it  
is  mostly  hydrolyzed  by  esterases  to  an  inactive  
derivative   (85%).   Only   15%   of   clopidogrel  
undergoes   CYP450   hepatic   metabolism   [4].  
The  active  metabolite   links  to  the  P2Y
12
  ADP  
receptor  and  causes  an  irreversible  blockade  of  
ADP  binding  [4].  Prasugrel  is  rapidly  hydrolyzed  
by  carboxyesterases   to   a   thiolactone,  which   is  
subsequently   metabolized   to   form   an   active  
???????????????????????? ?????? ??????????? ????
a  lesser  contribution  from  CYP2C19  with  respect  
to  clopidogrel   [4].  Prasugrel’s  active  metabolite  
binds  irreversibly  to  the  P2Y
12
  receptor.  By  contrast,  
ticagrelor  does  not  require  hepatic  conversion  into  
an  active  metabolite,  and  reversibly  binds  to  the  
ADP  receptor   [4].  Prasugrel  and  ticagrelor  have  
been  shown  to  be  more  potent  platelet  inhibitors  
???? ??? ????? ?? ????? ?????????? ????????????????
?????? ????????? ????? ???????????? ??? ??????????
patients.  This  discrepancy  comes  at  the  expense  
of  shifting  the  balance  towards  an  increased  risk  
of  bleeding  especially  in  some  patient  categories  
(old  age,  underweight  and  prior  cerebral  events)  
[7,8].  Moreover,  other  antiaggregant  drugs  such  
as  iloprost,  cilostazol  and  cangrelor  are  available  
and  might  be  considered  in  the  management  of  
????????????????????????????[4].
Several  CYP2C19??????????????????????????????
and   exhibit   functional   impairment,   which  
determines  the  poor  metabolizer  status  of  subjects.  
The  CYP2C19*2  polymorphism  (rs4244285)  is  a   part  of
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G681A  nucleotide  substitution  in  intron  4/exon  5  
junction,   which   introduces   a   splicing   defect,  
resulting  in  a  truncated,  nonfunctional  protein  
[4–6].   The   CYP2C19*2   variant   allele   has   a  
different  frequency  in  Caucasians  (15%),  Asians  
(30%)   and   African–Americans   (17%)   [4–6].  
The  CYP2C19*3   polymorphism   (rs4986893)  
is   a  G636A  nucleotide   substitution   in   exon  4  
that  creates  a  premature  stop  codon,  resulting  
in   a   truncated,  metabolically   inactive   protein  
[4–6].   The   CYP2C19*3   polymorphism   is   less  
frequent   in   Asians   (5%)   and   rare   in   both  
Caucasians   (0.04%)   and   African–Americans  
(0.4%)   [4–6].   Other   rare   variants   determine  
the   poor   metabolizer   phenotype,   such   as  
CYP2C19*4 ?????????????????????????????????
in  the  initiation  codon,  resulting  in  a  Met1Val  
substitution)   and   CYP2C19*5   (rs56337013,  
C1297T  substitution  in  exon  9,  resulting  in  an  
Arg433Trp  substitution)  [4].
??? ???? ?????? ???? ?????? ????? ?????????????
the   effect   of   CYP2C19*2   polymorphism   in  
modulating  platelet   function   in  ACS  patients  
undergoing  PCI  on  clopidogrel  [9].  The  *2  allele  
????????????????????????????????????????*2*2 
??????????? ????????? ???? ????????????? ???????
platelet   aggregation   than   *1*2   heterozygotes.  
?????????????????????????????????CYP2C19*2 
??????????????????????????? ???? ??????????????
and  different  clinical  settings  [4].
Most  importantly,  in  2009,  different  researchers  
simultaneously  demonstrated  that  CYP2C19*2  
is  a  determinant  of  the  occurrence  of  MACE,  
and  in  particular  stent  thrombosis,  in  different  
clinical  settings  of  patients  on  clopidogrel  [4].  By  
contrast,  Paré  et al.  showed  that  the  presence  of  
the  CYP2C19*2 polymorphism  in  patients  with  
????????????????????????????????????????????
was   not   associated   with   an   increased   risk   of  
MACE  [10].
????????????????????????????????????????????
co  genetics   are   available   in   the   literature  with  
apparently   different   responses   to   a   similar  
interrogation  [11–14].  These  apparent  discrepancies  
are   used   to   support   doubts   on   the  usefulness  
of   clopidogrel   pharmacogenetics.   The   first  
?????????????? ??? ???? et al.   on   data   from   six  
prospective  studies  indicated  that  the  CYP2C19*2  
polymorphism  is  associated  with  increased  risk  of  
MACE  and  in  particular  stent  thrombosis   [11].  
????????????????????????????et al.   [12]  and  the  
?????????????? ?????????????????? ????et al.  [13],  
???????????????????????????????????????????????
function  CYP2C19   allele   is   associated  with   a  
??????????????????????????????????????????????
thrombosis.  Accordingly,  with  these  observations,  
CYP2C19   genetic   information   identif ies  
approximately  30%  of  the  population  who  may  
be   less   likely   to   be   protected   from   recurrent  
ischemic  events  after  PCI  despite  treatment  with  
??????????????????????????????????????????????
????????? ??? ??? ???????? ?????????? et al.   came  
to   different   conclusions   [14].   By   including   all  
studies  in  which  clopidogrel  pharmacogenetics  
were   tested   relative   to   cardiovascular   events,  
independently   from  the   fact   that   they  studied  
????????????????????????????????????????????????
vascular  patients,  the  authors  concluded  that  the  
status  of  CYP2C19*2  carriers  was  not  clinically  
relevant   for  cardiovascular  outcomes  with   the  





The  hazard  of  drawing  conclusions  to  apply  
in   clinical   practice   by   acquiring   data   from  
???????????????????????????????????? ??????????
and   considering   similar   patients  with   greatly  
different   risks   of   cardiovascular   events,   and  
therefore   different   benefit   from   clopidogrel  
treatment  should  be  underlined.  Indeed,  in  their  
??????? ?? ???et al.  paid  particular  attention  to  
include  comparator  trials  of  clopidogrel  treatment  
response  in  which  both  treatment  and  comparator  
??????????? ?????????? ?????????????? ????
?????????????????????????????[14].  In  
these  studies,  populations  consisted  of  patients  
that,  in  large  part,  have  substantial  differences  







in  terms  of  risk  reduction  was  11%,  and  with  
documented  cardiovascular  disease  or  risk   for  
??????????????????????????? ??????????????????
????????????????????????????????????[14].
Concerning   CYP2C19   variants,   a   further  
polymorphism,   CYP2C19*17   (rs12248560),  
has  been  discovered  that  results  in  an  increased  
??????????????????????????????????????????????
??? ???? ??????????? ??????? ??? ???? ?????? ??????
causes   increased   transcription   [15].   In  patients  
undergoing   PCI,   Sibbing   et al.   showed   that  
CYP2C19*17   carrier   status   is   significantly  
associated  with  enhanced  response  to  clopidogrel,  
and  an  increased  risk  of  bleeding  [15].  This  datum  
1673future science group www.futuremedicine.com
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????????????????????????????????????????????????
need  of  its  introduction  in  the  diagnostic  panel  of  
clopidogrel  pharmacogenetic  variants  [5,6].
Other  polymorphisms  were   studied,  but   at  
present   clear   evidence   on   their   role   have   not  
been   achieved.   Contemporarily,   Mega   et al.  
[16]? ???????????????????????????????et al.  
[17]  evaluated  the  role  of  the  C3435CT  ABCB1  
?????????????????????????????????????????????
treatments   obtaining   opposite   results   on  
definition   of   the   risk   allele.   Bouman   et al.  
??????????????????????????????????????????????
polymorphism  of  PON1,   an  enzyme   involved  
in   clopidogrel   bioactivation,   in   patients   who  
underwent  stent  implantation  [18].  QQ192  PON1  
homozygous   patients   showed   a   considerably  
??????????????????????????????????????????????
??????????????????????????????????????????????
lower  plasma  concentration  of  clopidogrel  active  
metabolite   and   lower   platelet   inhibition   [18].  
Cayla   et al.,   evaluating   clinical,   angiographic  
and   genetic   factors,   identified   CYP2C19*2,  
CYP2C19*17,  C3435CT  ABCB1  and  PLA1/A2  
ITGB3????????????????PON1 polymorphisms  
independently   associated  with   early   coronary  
stent  thrombosis  [19].
????????????????????????????????????????????
has   accumulated   in   support   of   the   successful  
validation   and   clinical   application   of   the  
clopidogrel  pharmacogenetics  in  the  management  
of  patients  undergoing  PCI  [20,21].
In   order   to   introduce   clopidogrel  
pharmacogenetics  into  the  routine  management  
of   ACS   patients,   the   major   concerns   raised  
by   the   scientific   community   are   represented  
by   economic   issues   and   by   the   immediate  
availability  of  genetic  test  results.  Several  rapid  
systems  for  genetic  testing  are  now  commercially  
available  [20–22].  These  systems  guarantee  results  
??????????????????????????????????????????????????
be  used  by  unskilled  personnel,  have  a  cost  of  
approximately  €100,  which  will  be  amortized  
by  the  reduction  of  social  and  economic  costs  
of  the  management  of  clinical  complications  in  
?????????????????????????? ????????????????????????
issue   to   be   overcome   is   the   concern   deriving  
?????????????????????????????????????????????
of   genetic   test   results   by   clinicians.  This   is   a  
?????????????????????????????????????????????????
clopidogrel  pharmacogenetics,  but  in  general  for  
pharmacogenetics  and  systems  medicine  in  the  
present  and  in  the  future.
Conclusion & future perspective
The   scientif ic   knowledge   deriving   from  
genetics,   pharmacogenetics,   transcriptomics,  
metabolomics,   microbiome,   proteomics   and  
imaging   is   rapidly   growing   and   the   major  
challenge  is/will  be  to  translate  and  integrate  this  
mass  of   information  into  consolidated  disease  
knowledge  and  procedures  for  the  management  
of   patients.   Three   major   issues   need   to   be  
?????????? ???? ?????????? ???? ????????????
of   adequate   bioinformatics   approaches;;   the  
continuous   multidisciplinary   training   of   all  
the  experts   involved  in  the  process  (biologists,  
medical   specialists,   medical   geneticist   and  
bioinformatics  experts);;  and  the  development  
of   diagnosis   and   treatment   paths   under   the  









In   conclusion,   evidence   demonstrates   that  
genetic   variants,   in   particular   CYP2C19*2  
polymorphism,  are  independent  determinants  of  
???????????????????????????????????????????????????
risk  vascular  patients  on  antiplatelet  treatment.  
To  choose   the   ‘superior’  drug  on  the  basis  of  
large  trials  in  which  participants  with  different  
?????????????????????????????????? ??????????????
best  strategy.  We  believe  that  for  clopidogrel,  the  
??????????????????????????????????????????????????
the  evaluation  of  antiplatelet  treatments  tailored  
to  individual  characteristics  of  patients  (genetic  
????????????????????????????????????????????????
interactions   and   traditional   and   procedural  
risk   factors)   is   urgently   needed   to   identify  
therapeutic  strategies  that  will  provide  the  best  
?????????????????????????????? ??????????????????
clinical  setting.
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